◼ Archived
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
2 trends tracked about this subject — the full history, oldest to newest below.
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.